U.K. Train Operator c2c is All Aboard on the Determine

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
98
U.K. Train Operator c2c is All Aboard on the Determine Cloud Platform

CARMEL, IN--(Marketwired - May 9, 2017) - Determine, Inc. ( NASDAQ : DTRM ), the pioneering leader in global Source-to-Pay and Enterprise Contract Lifecycle Management (ECLM) Cloud Platform solutions, announced today that the award-winning U.K.-based train operator c2c, part of leading European train operator Trenitalia, has selected the Determine Cloud Platform to advance their strategic sourcing processes and contract management effectiveness.

As an innovative transportation leader, c2c (company name Trenitalia c2c) serves 26 stations in East London and South Essex, UK. The company, which traces its lineage back to the 1850's, was named Passenger Operator of the Year and London's best commuter operator in 2015. It holds the UK record for annual on-time performance -- 97.5%.

"We are proud that one of the leading train operators in the UK, c2c, has chosen the Determine Cloud Platform to manage its complex and growing sourcing solutions needs. As a company with highly sophisticated sourcing and contract infrastructure, the Determine Cloud Platform provides c2c with the advanced capabilities they require. A single source of data truth across all solutions, along with our powerful Business Process Management engine integrating all workflows, means the Determine Cloud Platform provides unparalleled collaboration and efficiency to increase competitiveness." -- Steve Potts, Chief Revenue Officer, Determine

Determine was selected by c2c through a competitive tender process. The company's procurement exercise set out to deliver a system to replicate their previous contract repository and e-procurement platform to a demanding deadline, on a flexible platform, and capable of meeting future needs.

"The Determine platform provides the foundation for c2c to drive efficiency in our supplier relations and procurement processes. It will ensure increased financial oversight of our contracts and enable us to comply with our regulatory requirements." -- Rob Appleyard, Head of Supply Chain Management, c2c

Determine was selected on the basis of providing the most capable product at a competitive price and the right delivery model.

"Onboarding c2c further expands Determine's already significant presence and market share in the transportation vertical -- which includes airlines, automobiles, rail and related industries. We look forward to putting our category expertise and Determine Cloud Platform to work helping c2c reach, and exceed, their business goals and showing another successful client the true value of Platformance." -- Jeffrey Grosman, Chief Operating Officer, Determine

About C2C c2c is the award-winning train operator running services between Fenchurch Street and Shoeburyness, serving 26 stations in East London and South Essex. Owned by Trenitalia, c2c is one of the UK's most punctual and popular train operators and over 43m journeys are made on our services every year.

Italian-based Trenitalia is one of Europe's leading rail operators and the passenger rail arm of FS Italiane Group. Trenitalia manages passenger services with long haul connections, both on high speed (Frecciarossa) and conventional lines, and regional and metropolitan services. Overall FS Italiane Group runs 8,000 trains a day, serving 600 million passengers and carrying 50 million tons of freight a year, over a network exceeding 16,700 kilometres.

For more information, please visit: www.c2c-online.co.uk

Supporting Resources Determine blog Determine on LinkedIn Determine on Twitter Determine Resources

About Determine, Inc. Determine, Inc. ( NASDAQ : DTRM ) is a leading global provider of SaaS Source-to-Pay and Enterprise Contract Lifecycle Management (ECLM) solutions. The Determine Cloud Platform provides procurement, legal and finance professionals analytics of their supplier, contract and financial performance. Our technologies empower customers to drive new revenue, identify savings, improve compliance and mitigate risk.

The Determine Cloud Platform seamlessly integrates with major ERP or third-party systems such as SAP, Oracle, Sage, QAD and Microsoft. Modular solutions can be configured to add more as needed to provide additional value beyond spend management. Our unified master database and business process approach empower users at every level to make more informed and smarter decisions.

For more information, please visit: www.determine.com .

Contact Media Relations: Rose Lee Determine Inc. +1.650.532.1590 pr@determine.com

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Stavian Group Eyes AI-Driven Southeast Asia Growth

Updated Category News Views 35

AI and Infrastructure: A New Chapter for Southeast Asia What does Southeast Asia's future look like with AI steering the ship? Well, there's a fresh breeze of change blowing, and right at the heart of it stands Stavian Group. At the recently held inaugural Fortune SEA500 Summit in Ho Chi Minh City, this conglomerate threw its hat into the ring, painting a vision of growth...

Continue Reading
Antengene’s AnTenGager-D2 Advances in Cancer Treatment

Updated Category News Views 51

Antengene's AnTenGager-D2 Offers Fresh Hope Alright, let's dig into the latest buzz from the 2026 Society for Immunotherapy of Cancer conference about Antengene's AnTenGager-D2 platform. If you're not into biotech lingo, buckle up, because this is a ride into the future of cancer treatments—where science fiction might soon become science fact. A Novel Approach to Tumor...

Continue Reading
Innovent's SINTBILO® Hits Primary Endpoint in Study

Updated Category News Views 119

Innovent's Latest Breakthrough with SINTBILO® One moment you're sipping coffee, the next you're staring at a clinical milestone. Innovent Biologics has shouted from the rooftops that their drug, SINTBILO® (tafolecimab injection), has wrapped up its Phase 3 CREDIT-5 study, snagging the primary endpoint with both hands. This isn't just any drug; it's marked as the first...

Continue Reading
ASTS Faces Class Action; Investors Beware of Pitfalls

Updated Category News Views 291

Securities Fraud Allegations Hit AST SpaceMobile Days like this remind me why we keep our eyes peeled in the stock game—AST SpaceMobile (NASDAQ: ASTS) is tangled in a web of legal drama, and it's something you can't brush off with a shrug. Class action lawsuits for securities fraud? That's like finding out the foundation's shaky beneath a skyscraper. If you've got skin...

Continue Reading
Gildan's Crisis: Investors Face Losses Amid Lawsuit

Updated Category News Views 245

Gildan Investors, Brace Yourself Poor old Gildan Activewear finds itself in hot water again, with a class action lawsuit cropping up like an unexpected storm on farmers' day. Any traders remotely involved with NYSE:GIL should pay damn close attention, because with a December 14, 2026 deadline looming, it's crunch time. The Root of the Lawsuit The plot thickens here,...

Continue Reading
Intelligent Communication Forum Eyes Global Ecosystem Shift

Updated Category News Views 595

China's Grand Vision for Intelligent Communication You know what they say about big ideas—they start in the most bustling of places. And here we are in Wuxi, a city's pulse pounding with ambition, hosting the 2026 China International Intelligent Communication Forum. Picture it: From November 8th to 10th, movers, shakers, and visionaries are scribbling new blueprints for...

Continue Reading
Cleaner Air in Bedroom May Stabilize Blood Sugar Levels

Updated Category News Views 321

Imagine a world where simply sleeping in cleaner air could affect your blood sugar. Seems far-fetched, I know. But that's where we're at with this new study out of NYU Langone Health. They're talking about using plain ol' portable air filters to help steady blood sugar levels for folks dealing with prediabetes. Turns out a cleaner bedroom might just hold the key to taming...

Continue Reading
Novo's Semaglutide Shows Promise in MASH Study

Updated Category News Views 337

Semaglutide, a name on the lips of many investors looking for breakthroughs, is making waves again. This time, the stir comes from recent findings in the MASH field, and it's got folks in white coats quite excited. Revolutionary Results from Novo Novo Nordisk has announced promising results from their phase 3 ESSENCE trial that looks into semaglutide's effects on a...

Continue Reading
Cultural Tech Fusion: The Asia-Pacific Way Forward

Updated Category News Views 0

A High-Tech Twist on Traditional Culture You ever walk into a room and see a robot perform kung fu? I'll admit, it caught me off guard at first. But that's exactly what happened at the "Enduring Heritage, Harmonious Asia-Pacific" special exhibition in Shenzhen. With all the usual high-ranking execs and cultural bigwigs there, nobody expected a showcase where Wing Chun...

Continue Reading
JNJ's Dual-Antigen Therapy Shows Promise in Prostate Cancer

Updated Category News Views 273

Exploring a New Front in Cancer Treatment Johnson & Johnson (NYSE: JNJ) just dropped a bombshell at the Society for Immunotherapy of Cancer (SITC) 2026 Annual Meeting, unveiling data that could reshape prostate cancer care. Their pioneering combo of pasritamig and JNJ-9401, a dual-antigen-targeted therapy, has the scientific community buzzing. Yeah, it's just Phase 1 baby...

Continue Reading

Top 5 Most Recently Viewed Articles

Market Reactions: Middle East Tensions and the Vance-Walz Debate

Updated Category News Views 71

Market Reactions to Middle East Tensions US stock futures are experiencing a downward trend as investors react to the escalating violence in the Middle East. With Iran claiming to have ceased its air bombardments on Israel, uncertainty still looms, as Israeli officials pledge a counterattack. This ongoing conflict has already impacted Wall Street, where equity values...

Continue Reading
Class Action Alert for Visa Inc. Shareholders Facing Losses

Updated Category News Views 91

Class Action Notification for Visa Inc. Shareholders The Gross Law Firm is reaching out to shareholders of Visa Inc. (NYSE: V) regarding an important class action that may affect them. If you purchased shares during a specific class period and have suffered losses, your participation could be significant in holding the company accountable. Understanding the Class Period...

Continue Reading
Coca-Cola's Earnings Report: Anticipated Insights and Analysis

Updated Category News Views 205

Coca-Cola's Earnings Report Overview The Coca-Cola Company (NYSE: KO) is on the cusp of unveiling its second-quarter financial results. Investors, analysts, and fans alike are closely watching what insights the beverage giant will provide during this crucial report. With notable figures in the U.S. market keeping an eye on Coca-Cola, the anticipation is palpable. Earnings...

Continue Reading
Maggiano's Unveils Gourmet Italian-American Classics Menu

Updated Category News Views 410

Introduction of Italian-American Classics at Maggiano's Maggiano's Little Italy is embracing the culinary heritage of Italian-American cuisine by introducing a new menu that reflects a dedication to high-quality ingredients and gourmet recipes. Under the expert guidance of award-winning Chef Anthony Amoroso, the restaurant's latest offerings promise to impress food...

Continue Reading
Recognizing Excellence: Pierce & O'Neill Founders Honored

Updated Category News Views 362

Pierce & O’Neill Founders Honored Among Top Attorneys Pierce & O’Neill, LLP, a renowned litigation boutique, is celebrating its founders, Jesse Pierce and Jack O’Neill, for their remarkable achievements in the legal field. Recently recognized in Lawdragon’s prestigious list of the 500 Leading Lawyers in America for 2025, this accolade showcases their exceptional...

Continue Reading